Morgan Stanley resumes coverage of Pfizer (PFE +0.1% to $28.37) at Overweight and gives the company a price target of $31.00. The rating comes as the EU authorizes the expanded use of Pfizer's blockbuster anti-bacterial vaccine Prevenar 13. Thirteen analysts rate Pfizer a Buy, six a Hold and two a Sell.